An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Stopped This is an internal decision based on prioritisations and no safety issues have been raised during the trial.

Conditions

• Kidney Transplant Rejection

Interventions

• DRUG: Imlifidase

Sponsor

Hansa Biopharma AB